Cough medicine repurposed to fight dementia with lewy bodies
NCT ID NCT04588285
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 2 trial tests whether ambroxol, a common cough medicine ingredient, can slow cognitive decline and improve symptoms in people with early dementia with Lewy bodies. 180 participants will receive either ambroxol or a placebo for 18 months. The study measures changes in thinking, daily function, and psychiatric symptoms.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Ambroxol (a cough medicine ingredient, repurposed as a potential brain treatment)
What this could lead to
If it works, this could point toward a treatment that slows cognitive decline and eases symptoms in early dementia with Lewy bodies.
What could go wrong
This is a Phase 2 trial, so it's still early. The drug may not work better than placebo, and high doses could cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DEMENTIA WITH LEWY BODIES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Haraldsplass Deaconess Hospital
RECRUITINGBergen, Norway
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Helse Fonna
RECRUITINGHaugesund, Haugesund, 5504, Norway
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
Contact
Contact
-
Oslo University Hospital
RECRUITINGOslo, Norway
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Stavanger University Hospital
RECRUITINGStavanger, Norway
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Trondheim University Hospital
RECRUITINGTrondheim, Norway
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University Hospital North-Norway
RECRUITINGTromsø, Norway
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University Hospital, Akershus
RECRUITINGHågån, Norway
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University Hospital, Akershus
RECRUITINGLørenskog, Norway
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact